BrightSpring Beats Q2, Slips Back to KKR's Exit Price
BrightSpring Health Services beat Q2 2026 EPS estimates and raised its full-year revenue outlook, but the stock retreated to within $1.23 of the $58.45 price at which KKR sold $857.5 million of shares
BrightSpring Q2 Beat Fades as Stock Nears KKR Exit Price
NEW YORK, August 13 —
BrightSpring Health Services, Inc. (BTSG) has retreated to within $1.23 of the price at which KKR sold $857.5 million of stock in June, despite beating Q2 2026 earnings estimates and raising its full-year revenue outlook. A business executing at 23% revenue growth and a 50x trailing P/E occupies uncomfortable territory when its largest seller's exit price becomes the market's anchor.
- Q2 2026 EPS of $0.45 beat the $0.40 estimate; BrightSpring has beaten consensus in three of its last four quarters.
- KKR sold 14.67 million shares at $58.45 on June 5, part of $1.73 billion in 90-day net insider selling.
- Trailing P/E of 50.0x, double the 24.8x healthcare industry average, compresses to 26.2x forward if consensus growth materializes.
When the Sponsor and the CEO Sell Together
The $857.5 million secondary offering KKR executed on June 5 (documented in a 424B7 prospectus) was not a routine portfolio rebalance. CEO Jon Rousseau exercised options at a $6.37 cost basis and sold 130,000 shares at $58.75 the same day; taken together with other insider transactions, net selling over the 90-day period reached approximately $1.73 billion, with zero shares acquired by any insider or affiliated entity. Insiders sell for many reasons, but coordinated exits by both the controlling sponsor and the chief executive, on the same day and in the same price band, with no countervailing purchases anywhere in the 90-day window, belong in the discount rate.
The Growth Story Has Numbers Behind It
BrightSpring Health Services operates through two segments: Pharmacy Solutions (infused, injectable, and oral medications) and Provider Services, which delivers home health, occupational and speech therapy, and ABA therapy to medically complex seniors across all 50 states. Trailing twelve-month revenue reached $14.37 billion, up 23% year-over-year, and the 12.4% gross margin reflects the thin-margin structure of pharmacy distribution; growth is a volume and mix story, with specialty and infusion driving higher margins within Pharmacy Solutions. Free cash flow of $1.03 billion on a trailing basis confirms the model converts revenue to cash; near-term headwinds include Inflation Reduction Act reimbursement pressure and customer exits in Home and Community Pharmacy.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| BTSG | $11.8B | 26.2x | +164.3% |
| SNEX | $8.4B | 14.7x | +61.8% |
| PACS | $7.2B | 16.8x | +291.6% |
| WAY | $4.7B | 13.1x | -30.9% |
| INDV | $4.6B | 7.9x | +67.3% |
| ALHC | $2.8B | 18.0x | -8.8% |
The Price That Settles the Argument
The stock briefly touched $72.91 in late July (confirmed by CEO Rousseau's tax withholding at that price on July 25), then retreated to $59.68 after Q2 results dropped 4.9%, landing almost exactly where KKR exited. The forward P/E of 26.2x demands the growth consensus is projecting; reimbursement pressure and mix headwinds are the risk to that path. American Century Companies' $229.5 million new position signals institutional conviction on the other side. Another Q3 EPS beat would validate the premium; a miss confirms the 50x trailing multiple had already priced what the business can deliver. Investors can stress-test the assumptions with the DCF calculator; run the free BrightSpring Health Services, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What were BrightSpring's Q2 2026 results?
BrightSpring reported Q2 2026 EPS of $0.45, beating the $0.40 consensus estimate. The company also raised its full-year revenue outlook, its third beat in four quarters.
Why did BrightSpring stock fall after Q2 earnings?
The stock dropped 4.9% after Q2 results and settled at $59.68, landing almost exactly where KKR exited its $857.5 million secondary offering in June. A stock trading at 50x trailing earnings has limited room for the market to withhold judgment on any negative signal.
Did KKR sell its BrightSpring shares?
KKR sold 14.67 million shares at $58.45 on June 5 in a secondary offering documented in a 424B7 prospectus. CEO Jon Rousseau sold 130,000 shares at $58.75 the same day, and net insider selling over the 90-day period reached approximately $1.73 billion with zero shares acquired by any insider or affiliated entity.
What is BrightSpring's P/E ratio?
BrightSpring trades at a trailing P/E of 50.0x, double the 24.8x healthcare industry average. If consensus growth materializes, the forward P/E compresses to 26.2x.
What businesses does BrightSpring operate?
BrightSpring operates two segments: Pharmacy Solutions, covering infused, injectable, and oral medications, and Provider Services, which delivers home health, occupational and speech therapy, and ABA therapy to medically complex seniors across all 50 states. Trailing twelve-month revenue reached $14.37 billion, up 23% year-over-year.
BrightSpring Health Services reported strong Q2 2026 results and raised its 2026 revenue outlook on July 31 — but shares fell 4.9% afterward and have retreated to $59.68, barely above the $58.45 at which KKR sold $857 million of stock in a June secondary offering. The question the market is sitting with: whether a stock up 166.5% over the past year has already priced in the growth story even as the underlying business keeps beating estimates.